| Margins | EBITDA margin fell from 19.9% to 8.9% YoY. |
|---|---|
| Order book | Basket of 13 molecules in Late Phase III development. |
| Demand visibility | CHF 10mn CDMO deliverables rescheduled to H2FY27. |
Growth
CDMO revenue declined 12.6% YoY; Marketable Molecules segment grew 48% driven by higher Cholesterol sales.
Outlook
CHF 10mn CDMO revenue deferred to H2FY27. Capex of CHF 4.9mn in Q1; net debt at CHF 153.6mn.
Risks
Margins hit by notional FX loss of ₹117.3mn and under-utilization due to rescheduled project deliverables.
Last quarter's promises, checked
Delivered
- Guided 15-20% FY26 CDMO ADC share → delivered 25% (= BEAT)
- Guided FY26 EBITDA margin 19% → delivered 19.3% (= BEAT)
- Guided FY26 Net Debt reduction → delivered CHF 11mn reduction (= BEAT)
Partly delivered
- Guided FY27 revenue growth → delivered -4.3% in Q1 due to deferments (= PARTIAL)
Missed
- Guided Q1FY27 interest cost ₹30-35cr → delivered ₹43cr (= MISS)
- Guided consistent CDMO growth → delivered 12.6% YoY decline (= MISS)
- Guided margin stability → delivered 8.9% vs 19.9% YoY (= MISS)
Investor Presentation filed with BSE, NSE: DCAL. Summary written with AI assistance from the document.
Dishman Carbogen Amcis Ltd: key numbers
- Share price
- ₹168.19
- Market cap
- ₹2,637 Cr
- Revenue (annual)
- ₹2,932 Cr
- Net profit (annual)
- ₹97.45 Cr
- P/E (TTM)
- 163.2×Sector 50.4×
- Promoter holding
- 59.32%+0.00% QoQ
- FII holding
- 6.86%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dishman Carbogen Amcis Ltd
All →Dishman Carbogen Amcis Debt & Borrowing: ₹4.17 Cr
Dishman Carbogen Amcis Ltd fixed the record date for interest and partial redemption of its NCDs (ISIN: INE385W07059). The redemption totals ₹4.17 Crore.
- Value
- ₹4.17 Cr
Dishman Carbogen Amcis Debt & Borrowing: ₹1.26 Cr
Dishman Carbogen Amcis Ltd has made the sixth quarterly interest payment of ₹1.26 Crore on its non-convertible debentures as per Regulation 57(1).
- Value
- ₹1.26 Cr
Dishman Carbogen Amcis Business Update
Dishman Carbogen Amcis' subsidiary, Carbogen Amcis AG, successfully completed a US FDA inspection at its Vionnaz, Switzerland site without any observations.
Dishman Carbogen Amcis Debt & Borrowing: ₹0.45 Cr
Dishman Carbogen Amcis Ltd paid the first quarterly interest of ₹0.45 Crore on its Non-Convertible Debentures (ISIN: INE385W07067), complying with SEBI regulations.
- Value
- ₹0.45 Cr
Dishman Carbogen Amcis Debt & Borrowing
Dishman Carbogen Amcis Ltd has fixed September 11, 2026, as the record date for the sixth quarterly interest payment on its non-convertible debentures.
Dishman Carbogen Amcis Annual Report
Dishman Carbogen Amcis Ltd submitted the Notice of its 19th Annual General Meeting and the Annual Report for FY 2025-26. The AGM is scheduled for September 30, 2026.